Literature DB >> 9793793

3-(Carboxyalkylthio) rifamycin S and SV derivatives inhibit human neutrophil functions.

S Spisani1, S Traniello, A M Onori, O Rizzuti, C Martuccio, L Cellai.   

Abstract

In order to further investigate the potential of rifamycins as antiinflammatory drugs, twenty-five semisynthetic rifamycins were tested at concentrations ranging from 10(-9) to 10(-5) M on in vitro human neutrophil functions such as locomotion, superoxide anion production, and degranulation, under different stimulatory conditions. They were also tested as antiproliferative agents on peripheral blood lymphocytes. The present semisynthetic derivatives are in general characterized by their carrying a hydrophilic substituent; they are rifamycin S or rifamycin SV derivatives carrying at C(3) either a carboxyalkyl side-chain or a glycosyl side-chain. Derivatives of the former group displayed inhibitory activities covering the whole range of activities tested, suggesting that the sum of these different effects could support their antiinflammatory activity in vivo. These derivatives, carrying a free carboxyl, are more water soluble than rifamycin SV at physiological pH, and may serve as antiinflammatory drugs for local administration, alternative to rifamycin SV, possibly giving higher efficacy and reduced side effects of pain and tissue swelling.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9793793     DOI: 10.1023/a:1022341909396

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  12 in total

1.  CD16 and CR3 receptors distinguish between the two mechanisms of tumour cytotoxicity in neutrophils.

Authors:  R Gavioli; S Spisani; A L Giuliani; E Cosulich; A Risso; S Traniello
Journal:  Br J Haematol       Date:  1991-10       Impact factor: 6.998

2.  Rifamycins inhibit human neutrophil functions: new derivatives with potential antiinflammatory activity.

Authors:  S Spisani; S Traniello; C Martuccio; O Rizzuti; L Cellai
Journal:  Inflammation       Date:  1997-08       Impact factor: 4.092

Review 3.  Current concepts: immunology. Neutrophils in human diseases.

Authors:  H L Malech; J I Gallin
Journal:  N Engl J Med       Date:  1987-09-10       Impact factor: 91.245

4.  Rifampin therapy in rheumatoid arthritis.

Authors:  S E Gabriel; D L Conn; H Luthra
Journal:  J Rheumatol       Date:  1990-02       Impact factor: 4.666

5.  In vivo and in vitro suppression of humoral and cellular immunological response by rifampicin.

Authors:  E Păunescu
Journal:  Nature       Date:  1970-12-19       Impact factor: 49.962

6.  Prevention of appearance of radiological lesions in early rheumatoid arthritis: a randomized, single-blind study comparing intra-articular rifamycin with auranofin.

Authors:  I Caruso; S Santandrea; P Sarzi Puttini; F Montrone; L Boccassini; V Azzolini; M Cazzola; D Dell'Acqua
Journal:  J Int Med Res       Date:  1992-02       Impact factor: 1.671

7.  The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor.

Authors:  C Calleja; J M Pascussi; J C Mani; P Maurel; M J Vilarem
Journal:  Nat Med       Date:  1998-01       Impact factor: 53.440

8.  Rifamycin SV in local treatment of synovitis--a clinical, arthroscopic and pharmacologic evaluation.

Authors:  S Lindblad; E Hedfors; A S Malmborg
Journal:  J Rheumatol       Date:  1985-10       Impact factor: 4.666

9.  Rifamycin SV versus triamcinolone in local treatment of rheumatoid synovitis.

Authors:  A Marchesoni; L Sinigaglia; R Ranza; M Varenna; N Battafarano; S Tosi
Journal:  Scand J Rheumatol       Date:  1993       Impact factor: 3.641

10.  Leukocyte locomotion and chemotaxis. New methods for evaluation, and demonstration of a cell-derived chemotactic factor.

Authors:  S H Zigmond; J G Hirsch
Journal:  J Exp Med       Date:  1973-02-01       Impact factor: 14.307

View more
  2 in total

1.  Interaction of rifalazil with oxidant-generating systems of human polymorphonuclear neutrophils.

Authors:  M T Labro; V Ollivier; C Babin-Chevaye
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

2.  An in vitro investigation of the anti-inflammatory properties of potassium humate.

Authors:  Gisela Käthe Jooné; Constance Elizabeth Jansen van Rensburg
Journal:  Inflammation       Date:  2004-06       Impact factor: 4.092

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.